Please wait while the formulary information is being retrieved.
IDAMYCIN PFS (IDARUBICIN HCL)
- Acute myeloid leukemia
1 mg/mL intravenous solution
- Inject 12 mg/m2 by intravenous route once daily over 10 to15 minutes for 3 days
idarubicin 1 mg/mL intravenous solution
- Inject 12 mg/m2 by intravenous route once daily over 10 to15 minutes for 3 days
1 mg/mL intravenous solution
- Inject 12 mg/m2 by intravenous route once daily over 10 to15 minutes for 3 days
Acute myeloid leukemia
- Inject 12 mg/m2 by intravenous route once daily over 10 to15 minutes for 3 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- ado-trastuzumab emtansine
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Herceptin
- Kadcyla
- trastuzumab
- Versacloz
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Bone marrow depression
- Cardiac arrhythmia
- Cardiomyopathy
- Chronic heart failure
- Disease of liver
- Kidney disease with reduction in GFR
- Pregnancy
- Severe infection
Severe
Moderate
- Anemia
- Enterocolitis
- Gastrointestinal perforation
- Myocarditis
- Pericarditis
IDAMYCIN PFS (IDARUBICIN HCL)
- Acute myeloid leukemia
- Bullous dermatitis
- Hemorrhage
- Infection
- Leukopenia
- Stomatitis
- Thrombocytopenic disorder
- Abdominal pain with cramps
- Alopecia
- Diarrhea
- Headache disorder
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Cardiac arrhythmia
- Cardiomyopathy
- Chemotherapy-induced hyperuricemia
- Chronic heart failure
- Injection site sequelae
- Postirradiation erythema
- Seizure disorder
- Tissue necrosis
- Altered mental status
- Fever
- Peripheral neuropathy
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Allergic dermatitis
- Enterocolitis
- Extravasation injury
- Intestinal perforation
- Kidney disease with reduction in GFR
- Radiation recall syndrome
- Severe bone marrow depression
- Skin rash
- Urticaria
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Idarubicin (Inj)
Safety and efficacy not established in children.
- 1 Day – 13 Years
- Safety and efficacy not established in children.
Idarubicin
- Severity Level:
D
- Additional Notes:
Contraindicated
Idarubicin
Molecular wt low enough for possible excretion;Carcinogenic in animal studies
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Molecular wt low enough for possible excretion;Carcinogenic in animal studies |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Idarubicin
General-Assess bone marrow reserves in the elderly as they may be lower, thus increasing the risk of prolonged suppression. Cardiovascular-Cardiotoxicity may be more frequent in elderly. Renal-age-related renal dysfunction may require dose reduction.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Idarubicin must be given only by injection slowly into a vein. Do not give by injection into a muscle or under the skin. If this medication accidentally leaks into the skin/muscle around the injection site, it may cause severe damage.<br /><br />Tell your doctor right away if you notice redness, pain, or swelling at or near the injection site. This medication may rarely cause serious (rarely fatal) heart problems (including heart failure). This may occur both during treatment or after treatment is completed.<br /><br />The risk of heart problems is affected by your dose, medical history (including heart disease, radiation treatment to the chest area, current infections, anemia), and previous use of this and other drugs (including doxorubicin). Tell your doctor right away if you notice symptoms such as irregular heartbeat, shortness of breath, swelling ankles/feet, unusual tiredness, or unusual/sudden weight gain. Idarubicin may cause certain severe blood and bone marrow disorders (low red blood cells/white blood cells/platelets).<br /><br />This can affect your body's ability to stop bleeding or fight infection. Tell your doctor right away if you develop easy bleeding/bruising or signs of infection (e.g., fever, chills, persistent sore throat). Very rarely, people with cancer who are treated with this type of medication have developed other cancers (e.g., secondary leukemia).<br /><br />The risk may be increased when this medication is given with certain anti-cancer drugs or radiation treatment. Consult your doctor for more details. Before starting treatment with this medication, tell your doctor if you have liver or kidney problems. Your dose may need to be adjusted.
| Acute myeloid leukemia | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| 0-9 | A-Z |
|---|---|
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
Formulary Reference Tool